Published in Clin Vaccine Immunol on August 01, 2012
Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev (2014) 1.03
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine. J Immunol (2012) 1.01
Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis (2013) 0.98
PspA family distribution, antimicrobial resistance and serotype of Streptococcus pneumoniae isolated from upper respiratory tract infections in Japan. PLoS One (2013) 0.83
A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA). Vaccine (2013) 0.83
Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies. Clin Vaccine Immunol (2014) 0.81
Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles. Acta Biomater (2013) 0.81
Viability and virulence of pneumolysin, pneumococcal surface protein A, and pneumolysin/pneumococcal surface protein A mutants in the ear. JAMA Otolaryngol Head Neck Surg (2013) 0.80
Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae. PLoS One (2015) 0.79
Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A. Clin Vaccine Immunol (2013) 0.78
Rationale and prospects for novel pneumococcal vaccines. Hum Vaccin Immunother (2016) 0.77
A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood. Sci Rep (2017) 0.77
Silver polyvinyl pyrrolidone nanoparticles exhibit a capsular polysaccharide influenced bactericidal effect against Streptococcus pneumoniae. Front Microbiol (2014) 0.76
A Synthetic Virus-Like Particle Streptococcal Vaccine Candidate Using B-Cell Epitopes from the Proline-Rich Region of Pneumococcal Surface Protein A. Vaccines (Basel) (2015) 0.75
Towards Identifying Protective B-Cell Epitopes: The PspA Story. Front Microbiol (2017) 0.75
Role of Streptococcus pneumoniae Proteins in Evasion of Complement-Mediated Immunity. Front Microbiol (2017) 0.75
STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III. J Exp Med (1944) 24.08
Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science (2001) 21.99
Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med (1982) 6.56
Phagocytosis of microbes: complexity in action. Annu Rev Immunol (2001) 5.49
Pattern recognition receptors: doubling up for the innate immune response. Cell (2002) 4.84
Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A (2003) 4.56
Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med (1987) 3.94
Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun (1990) 3.66
Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun (1999) 3.39
Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun (2000) 3.30
Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol (1994) 3.12
Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med (1984) 3.02
The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia. Infect Immun (1999) 2.94
Truncated forms of PspA that are secreted from Streptococcus pneumoniae and their use in functional studies and cloning of the pspA gene. J Bacteriol (1992) 2.80
The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci U S A (2002) 2.72
Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis (2000) 2.55
Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis (1997) 2.50
Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun (2000) 2.48
Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar typhimurium vaccine. Infect Immun (2002) 2.25
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med (1970) 2.08
Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J Immunol (2003) 1.93
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H. Infect Immun (1999) 1.87
Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens. Infect Immun (1989) 1.86
Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun (2001) 1.74
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev Infect Dis (1983) 1.63
Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae. Infect Immun (2003) 1.54
Genetic control of the susceptibility to pneumococcal infection. Curr Top Microbiol Immunol (1986) 1.50
The virulence function of Streptococcus pneumoniae surface protein A involves inhibition of complement activation and impairment of complement receptor-mediated protection. J Immunol (2004) 1.37
Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect Immun (2007) 1.22
Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide. Infect Immun (2004) 1.21
Pneumococcal surface protein A (PspA) family distribution among clinical isolates from adults over 50 years of age collected in seven countries. J Med Microbiol (2006) 1.20
Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. N Engl J Med (1978) 1.20
Activation of CR3-mediated phagocytosis by MSP requires the RON receptor, tyrosine kinase activity, phosphatidylinositol 3-kinase, and protein kinase C zeta. J Leukoc Biol (2003) 1.19
PspA and PspC minimize immune adherence and transfer of pneumococci from erythrocytes to macrophages through their effects on complement activation. Infect Immun (2007) 1.17
Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb Pathog (2007) 1.13
Signaling properties of CR3 (CD11b/CD18) and CR1 (CD35) in relation to phagocytosis of complement-opsonized particles. J Immunol (1993) 1.07
Roles of the alternative complement pathway and C1q during innate immunity to Streptococcus pyogenes. J Immunol (2006) 1.06
Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol (2010) 1.06
The complement system: an overview. Methods Mol Biol (2000) 1.05
Complement-mediated phagocytosis of herpes simplex virus by granulocytes. Binding or ingestion. J Clin Invest (1989) 1.03
Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J Immunol (2006) 1.03
C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol (1999) 1.01
CD44-mediated phagocytosis induces inside-out activation of complement receptor-3 in murine macrophages. Blood (2007) 0.97
Gram-negative bacteria and phagocytic cell interaction mediated by complement receptor 3. FEMS Immunol Med Microbiol (2002) 0.96
Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun (2010) 0.94
Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses. FEMS Immunol Med Microbiol (2003) 0.87
Role of complement in host defense against bacterial infection. Microbes Infect (1999) 0.85
Kepler planet-detection mission: introduction and first results. Science (2010) 6.23
Genetic basis for the new pneumococcal serotype, 6C. Infect Immun (2007) 5.27
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Evolutionary genetics of the capsular locus of serogroup 6 pneumococci. J Bacteriol (2004) 3.81
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Basophils enhance immunological memory responses. Nat Immunol (2008) 3.35
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Precise segmental renal artery clamping under the guidance of dual-source computed tomography angiography during laparoscopic partial nephrectomy. Eur Urol (2012) 2.95
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2012) 2.78
Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis (2005) 2.67
Differential genome-wide profiling of tandem 3' UTRs among human breast cancer and normal cells by high-throughput sequencing. Genome Res (2011) 2.61
Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). Mol Vis (2005) 2.55
Intrasarcoplasmic amyloidosis impairs proteolytic function of proteasomes in cardiomyocytes by compromising substrate uptake. Circ Res (2005) 2.49
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A (2013) 2.49
Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol (2006) 2.48
Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis (2003) 2.46
PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol (2008) 2.42
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol (2004) 2.33
FIT interacts with AtbHLH38 and AtbHLH39 in regulating iron uptake gene expression for iron homeostasis in Arabidopsis. Cell Res (2008) 2.33
Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol (2002) 2.28
Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res (2012) 2.27
Gene therapy restores vision-dependent behavior as well as retinal structure and function in a mouse model of RPE65 Leber congenital amaurosis. Mol Ther (2005) 2.27
Subintimal angioplasty for below-the-ankle arterial occlusions in diabetic patients with chronic critical limb ischemia. J Endovasc Ther (2009) 2.22
Emerging role for autophagy in the removal of aggresomes in Schwann cells. J Neurosci (2003) 2.21
Seroprevalence of Toxoplasma gondii infection in dairy goats in Shaanxi Province, Northwestern China. Parasit Vectors (2011) 2.19
Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun (2002) 2.15
A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J (2005) 2.13
Streptococcus pneumoniae forms surface-attached communities in the middle ear of experimentally infected chinchillas. J Infect Dis (2009) 2.10
Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem (2002) 2.07
Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity (2007) 2.07
Production of a unique pneumococcal capsule serotype belonging to serogroup 6. Microbiology (2009) 2.07
Potential bridges for HIV infection to men who have sex with men in Guangzhou, China. AIDS Behav (2006) 2.06
The Arabidopsis histidine phosphotransfer proteins are redundant positive regulators of cytokinin signaling. Plant Cell (2006) 2.06
Tumor susceptibility of Rassf1a knockout mice. Cancer Res (2005) 2.03
Decoupling suspension controller based on magnetic flux feedback. ScientificWorldJournal (2013) 2.03
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem (2003) 1.97
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res (2003) 1.94
Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res (2010) 1.93
Improvement of the survival of human autologous fat transplantation by using VEGF-transfected adipose-derived stem cells. Plast Reconstr Surg (2009) 1.93
A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys J (2003) 1.93
Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun (2004) 1.91
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Influenza A virus facilitates Streptococcus pneumoniae transmission and disease. FASEB J (2010) 1.87
Catalytic domain of PRL-3 plays an essential role in tumor metastasis: formation of PRL-3 tumors inside the blood vessels. Cancer Biol Ther (2004) 1.84
Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun (2006) 1.80
The post-stishovite phase transition in hydrous alumina-bearing SiO2 in the lower mantle of the earth. Proc Natl Acad Sci U S A (2007) 1.80
Role of Escherichia coli O157:H7 virulence factors in colonization at the bovine terminal rectal mucosa. Infect Immun (2006) 1.72
Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry (2002) 1.71
Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun (2003) 1.70
Retracted Application and implementation of selective tissue microdissection and proteomic profiling in neurological disease. Neurosurgery (2009) 1.69
AAV-mediated gene therapy for retinal degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest Ophthalmol Vis Sci (2008) 1.68
Design of efficient thermally activated delayed fluorescence materials for pure blue organic light emitting diodes. J Am Chem Soc (2012) 1.68
The RANKL signaling axis is sufficient to elicit ductal side-branching and alveologenesis in the mammary gland of the virgin mouse. Dev Biol (2009) 1.67
Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem (2007) 1.66
Automated clinical reminders for primary care providers in the care of CKD: a small cluster-randomized controlled trial. Am J Kidney Dis (2011) 1.66
Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett (2002) 1.64
Reciprocal regulation of Akt and Oct4 promotes the self-renewal and survival of embryonal carcinoma cells. Mol Cell (2012) 1.63
Protein kinase g positively regulates proteasome-mediated degradation of misfolded proteins. Circulation (2013) 1.62
Characterization of the osteoblast-specific transmembrane protein IFITM5 and analysis of IFITM5-deficient mice. J Bone Miner Metab (2010) 1.61
A novel LacZ reporter mouse reveals complex regulation of the progesterone receptor promoter during mammary gland development. Mol Endocrinol (2002) 1.61
Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res (2010) 1.55
Mn2+-dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect Immun (2006) 1.55
Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24. Diabetes (2004) 1.54
Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun (2008) 1.54
PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun (2004) 1.53
An analysis of T cell intrinsic roles of E2A by conditional gene disruption in the thymus. J Immunol (2002) 1.52
von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med (2007) 1.52
Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol (2013) 1.51
Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity (2002) 1.50
Alcohol-induced adipogenesis in bone and marrow: a possible mechanism for osteonecrosis. Clin Orthop Relat Res (2003) 1.49
Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood (2007) 1.49
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell (2010) 1.48
Fyn tyrosine kinase is a downstream mediator of Rho/PRK2 function in keratinocyte cell-cell adhesion. J Cell Biol (2002) 1.48
Anti-tumorigenicity of dietary α-mangostin in an HT-29 colon cell xenograft model and the tissue distribution of xanthones and their phase II metabolites. Mol Nutr Food Res (2012) 1.48
Retrograde transdorsal-to-plantar or transplantar-to-dorsal intraluminal re-entry following unsuccessful subintimal angioplasty for below-the-ankle arterial occlusion. J Endovasc Ther (2010) 1.47
Cloning and functional analysis of a novel DREB1/CBF transcription factor involved in cold-responsive gene expression in Zea mays L. Plant Cell Physiol (2004) 1.46
Antibody-independent, CD4+ T-cell-dependent protection against pneumococcal colonization elicited by intranasal immunization with purified pneumococcal proteins. Infect Immun (2007) 1.45
Discovery of novel secreted virulence factors from Salmonella enterica serovar Typhimurium by proteomic analysis of culture supernatants. Infect Immun (2010) 1.44
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Macrophage Turnover Kinetics in the Lungs of Mice Infected with Streptococcus pneumoniae. Am J Respir Cell Mol Biol (2007) 1.42
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. J Atheroscler Thromb (2014) 1.42
Experimental and clinical observations of 99mTc-MIBI uptake correlate with P-glycoprotein expression in lung cancer. Nucl Med Commun (2007) 1.41
Lung-specific overexpression of CC chemokine ligand (CCL) 2 enhances the host defense to Streptococcus pneumoniae infection in mice: role of the CCL2-CCR2 axis. J Immunol (2007) 1.41
PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest (2009) 1.41
Regulation of 4-hydroxynonenal-mediated signaling by glutathione S-transferases. Free Radic Biol Med (2004) 1.40
Parkinson's disease patients with pain suffer from more severe non-motor symptoms. Neurol Sci (2014) 1.40
Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol (2004) 1.39
Gold-nanocrystal-enhanced bioluminescent nanocapsules. ACS Nano (2014) 1.39